• Submit to Pharmaceutics Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [60 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Marfo, K
• Altshuler, J
• Lu, A
• [+] on Google Scholar
• Marfo, K
• Altshuler, J
• Lu, A
• [+] on PubMed
• Marfo, K
• Altshuler, J
• Lu, A

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceutics 2010, 2(3), 291-299; doi:10.3390/pharmaceutics2030291

Review

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients

Kwaku Marfo ¹ , Jerry Altshuler ²  and Amy Lu ^1,*

¹ Montefiore-Einstein Transplant Center,111 East 210th Street, Bronx, NY 10467, USA ² School of Pharmacy, State University at Buffalo, 110 Cooke Hall, Buffalo, NY 14215, USA

* Author to whom correspondence should be addressed.

Received: 5 August 2010; in revised form: 23 August 2010 / Accepted: 30 August 2010 / Published: 9 September 2010

(This article belongs to the Special Issue Pharmacokinetics and Pharmacodynamics in Children: Establishing Differences from Adults)

Download PDF Full-Text [60 KB, uploaded 9 September 2010 14:21 CEST]

Abstract: Tacrolimus is a calcineurin inhibitor immunosuppressant that has seen considerable use in both adult and pediatric solid organ transplant recipients. Though there is much pharmacokinetic data available for tacrolimus in the adult population, the literature available for children is limited. Furthermore, very little is known about the pharmacogenomic differences in the two patient groups. Based on what information is currently available, clinically significant differences may exist between the two populations in terms of absorption, distribution, metabolism and elimination. In addition, inherent physiological differences exist in the young child including: less effective plasma binding proteins, altered expression of intestinal P-glycoprotein, and increased expression of phase 1 metabolizing enzymes, therefore one would expect to see clinically significant differences when administering tacrolimus to a child. This paper examines available literature in an attempt to summarize the potential pharmacokinetic and pharmacogenomic variability that exists between the two populations.

Keywords: tacrolimus; FK-506; pharmacokinetics; pharmacogenomics; pediatric transplant

Article Statistics

Cite This Article